Schizophrenia remains one of the most debilitating neuropsychiatric conditions worldwide, requiring sustained pharmacological intervention to manage positive symptoms, prevent relapse, and support functional recovery. Clinical practice guidelines universally recommend monotherapy as the standard of care for maintenance treatment. Nevertheless, clinicians in real-world psychiatric settings frequently encounter treatment resistance, incomplete symptom remission, and adverse drug reactions. Consequently, antipsychotic polypharmacy—the concurrent coprescribing of two or more antipsychotic agents—has emerged as a widespread therapeutic reality. Understanding longitudinal pharmacological patterns provides clinicians with crucial insights into how treatment choices adapt to newly introduced pharmacotherapies and changing clinical paradigms over decades.

Long-Term Shifts Across Two Decades of Antipsychotic Use

A comprehensive 21-year territory-wide cohort study conducted in Hong Kong tracked all adult patients diagnosed with schizophrenia between 2004 and 2024 to map prescribing trajectories. Researchers observed that overall antipsychotic exposure remained remarkably consistent throughout the study period, showing only a slight downward trend with an average annual percentage change of minus 0.40 percent. However, this apparent stability masked profound transformations among individual therapeutic drug classes. Prescribing habits revealed a clear crossover transition from first-generation antipsychotics toward second-generation antipsychotics over the initial observation decade. Although the growth rate of second-generation agents gradually leveled off in subsequent years, they firmly established therapeutic dominance across inpatient and outpatient care settings. These changes reflect a global therapeutic movement aimed at minimizing disabling motor complications such as acute dystonia, parkinsonism, and tardive dyskinesia associated with conventional dopamine receptor antagonists.

Dominance of Second-Generation Agents and Clozapine Utilization

Among the second-generation agents analyzed in the multi-decade cohort, olanzapine emerged as the single most prevalent antipsychotic medication, utilized by 20.6 percent of the patient cohort by 2024. Clinicians favored olanzapine due to its potent antipsychotic efficacy, rapid tranquilizing properties, and versatile delivery options. However, this heavy reliance introduces significant cardiometabolic liabilities, including severe weight gain, dyslipidemia, and new-onset type 2 diabetes mellitus. In contrast, clozapine utilization expanded steadily over the study timeframe but peaked at a modest 7.5 percent by 2024. Because clozapine remains the undisputed gold standard for treatment-resistant schizophrenia, its low market penetration suggests ongoing underutilization. Prescribers frequently delay or avoid clozapine initiation because of stringent hematological monitoring requirements, fears of agranulocytosis, myocarditis, and severe gastrointestinal hypomotility.

Evolution of Long-Acting Injectables in Relapse Prevention

Long-acting injectable antipsychotics represent an essential therapeutic modality designed to overcome treatment non-adherence, which constitutes the leading driver of psychotic relapses and psychiatric hospital readmissions. Curiously, the total utilization rate of long-acting injectables experienced an overall decline over the 21-year interval, decreasing at an average annual percentage change of minus 0.92 percent. This drop occurred primarily because psychiatrists phased out conventional first-generation depot formulations, including fluphenazine and haloperidol decanoate. Conversely, the uptake of second-generation long-acting injectables grew substantially, driven predominantly by long-acting paliperidone palmitate and long-acting aripiprazole formulations. These second-generation depot options provide reliable plasma drug concentrations while mitigating peak-dose extrapyramidal symptoms, thereby supporting relapse prevention in vulnerable outpatient populations.

Emergence and Trajectory of Antipsychotic Polypharmacy

Despite clinical practice guidelines advocating monotherapy, real-world data demonstrated a concerning upward trajectory in coprescribing. The prevalence of antipsychotic polypharmacy exhibited a biphasic pattern: it initially declined from 24.0 percent in 2004 to a nadir of 22.4 percent in 2011, before climbing steadily to 28.0 percent by 2024, with a positive average annual percentage change of 0.74 percent. By 2024, nearly three out of every ten treated patients received multiple concurrent antipsychotics. The most prevalent regimen combined oral aripiprazole with oral olanzapine, accounting for 5.68 percent of all coprescriptions. Other frequent pairings included oral amisulpride with oral olanzapine at 4.22 percent, and long-acting injectable paliperidone combined with oral olanzapine at 4.05 percent. These patterns illustrate that prescribers frequently combine agents with distinct receptor-binding profiles to counterbalance metabolic adverse effects or augment partial dopamine antagonism.

Clinical Implications, Cardiometabolic Risks, and Deprescribing

The rising prevalence of multi-drug regimens raises vital clinical concerns regarding cumulative pharmacological burden, drug-drug interactions, and adverse events. Combining two or more antipsychotics frequently leads to supra-therapeutic dopamine D2 receptor occupancy, elevating risks of hyperprolactinemia, sexual dysfunction, and cognitive blunting. Furthermore, stacking agents such as olanzapine and amisulpride heightens cardiovascular morbidity through additive QTc prolongation and synergistic metabolic decompensation. Because many combinations arise unintentionally during prolonged cross-titrations or hospital discharges, clinicians must conduct structured medication reconciliations at every follow-up. Periodic medication reviews should actively identify candidates for rational deprescribing. Tapering redundant secondary antipsychotics down to an optimized monotherapy regimen can restore functional clarity, reduce adverse effect loads, and preserve overall physical health.

Optimizing Evidence-Based Regimens for Schizophrenia

To curb irrational polypharmacy, mental health professionals must adopt rigorous, sequential clinical pathways when managing schizophrenia. First, prescribers should ensure an adequate trial of monotherapy at optimal therapeutic doses for a minimum of four to six weeks before deeming any treatment unsuccessful. Second, clinicians must assess treatment adherence objectively before switching or augmenting agents. Third, when a patient meets established criteria for treatment resistance following two unsuccessful monotherapy trials, psychiatrists should prioritize prompt clozapine initiation rather than reflexively layering multiple second-generation oral agents. When polypharmacy is clinically unavoidable, doctors must select mechanistically rational pairings—such as partial dopamine agonist augmentation—and execute comprehensive, routine metabolic, cardiac, and motor screening to protect long-term patient well-being.

Frequently Asked Questions

What constitutes antipsychotic polypharmacy in schizophrenia management?

Antipsychotic polypharmacy refers to the concurrent prescription of two or more distinct antipsychotic medications for a single patient. While guidelines recommend single-agent therapy, psychiatrists often utilize polypharmacy during cross-titration switches, to augment treatment response in refractory disease, or to mitigate secondary adverse drug effects.

Why is olanzapine frequently combined with aripiprazole?

Clinicians frequently pair olanzapine with aripiprazole because aripiprazole acts as a partial dopamine D2 and 5-HT1A agonist. This unique pharmacodynamic mechanism can counteract olanzapine-induced hyperprolactinemia, mitigate excessive sedation, and attenuate metabolic weight gain while optimizing therapeutic symptom control in partial treatment responders.

How should clinicians approach antipsychotic deprescribing?

Clinicians should approach deprescribing systematically by identifying stable patients on dual regimens who lack clear clinical rationales for multiple agents. The secondary antipsychotic should be tapered slowly over several months while closely monitoring positive symptoms, relapse indicators, withdrawal dyskinesias, and cardiometabolic parameters.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Healthcare professionals must use their clinical judgment and verify details against current prescribing guidelines. Refer to the latest local and national guidelines for clinical practice.

References

Deng EK et al. Evolving patterns of antipsychotic use and polypharmacy for schizophrenia in Hong Kong: a 21-year longitudinal study. Psychiatry Res. 2026 Oct. doi: 10.1016/j.psychres.2026.117346. PMID: 42551239.

Keepers GA et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry. 2020 Sep 1;177(9):868-872.

Correll CU et al. Antipsychotic Polypharmacy: A Worldwide Systematic Review and Meta-analysis of Its Prevalence and Correlates. J Clin Psychiatry. 2017 Jul;78(7):e755-e765.